Prognostic value of [BCLI/IGH] genes juxtaposition and MDRI gene expression in treatment resistant B-NHL

The translocation t[11;14] [q13; q32,] has been known neoplasia for many years found in a variety of B cell malignancies. Through this rearrangement, CCND1/PRAD-1/BCL1 on chromosome 11 becomes juxtaposition to the active immunoglobulin heavy chain [IgH] enhancer on chromosome. MDR1 gene expression lead to overproduction P-gp which leads to chemotherapy resistance caused poor prognosis and short survival [OS and DFS] in B-NHL. To evaluate BCL1/ IgH juxtaposition by FISH and mdr-1 protein expression by immunohistochemistry in B-NHL. To clarify if these genes have some relevance to developing treatment resistance of B-NHL and their correlation with clinical outcome. This is a retrospective study of fifty three bone marrow biopsy samples [fixed and paraffin embedded bone marrow biopsy] for patients with BNHL. In this study t[11;14] detected by FISH was positive in [64.2%] and it was [66. 7%], [64.3%] and [60%] in Mantle cell lymphoma [MCL], Small cell lymphoma [SCL], and Large cell lymphoma [LCL] respectively. The detection frequency of MDR1/ P- glycoprotein [P-gp] by immnunohistochemistry in MCL, SCL and LCL, is [80%], [82%] and [80%] respectively. In this study the frequency of t[11;14] detection by FISH and MDR1/P-gp expression by immnunohistochemistry in our study was consistent with other studies and considered as a marker of diagnostic and poor prognostic for chemotherapy resistance in B-NHL. Presence of both expressions in a patients means very bad prognosis and resistant to chemotherapy. Determining MDR-1/P-gp and t[11;14] in B-NHL is important prior to treatment to allow the design of novel drug regimens containing agent that reverse MDR function